Last Updated: May 3, 2026

ZURNAI (AUTOINJECTOR) Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

When do Zurnai (autoinjector) patents expire, and what generic alternatives are available?

Zurnai (autoinjector) is a drug marketed by Purdue Pharma Lp and is included in one NDA. There are two patents protecting this drug.

This drug has seven patent family members in five countries.

The generic ingredient in ZURNAI (AUTOINJECTOR) is nalmefene hydrochloride. There are four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the nalmefene hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zurnai (autoinjector)

A generic version of ZURNAI (AUTOINJECTOR) was approved as nalmefene hydrochloride by PURDUE PHARMA LP on February 8^th, 2022.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for ZURNAI (AUTOINJECTOR)?
What are the global sales for ZURNAI (AUTOINJECTOR)?
What is Average Wholesale Price for ZURNAI (AUTOINJECTOR)?

Summary for ZURNAI (AUTOINJECTOR)

International Patents:	7
US Patents:	2
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZURNAI (AUTOINJECTOR)

US Patents and Regulatory Information for ZURNAI (AUTOINJECTOR)

ZURNAI (AUTOINJECTOR) is protected by two US patents and one FDA Regulatory Exclusivity.

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Purdue Pharma Lp	ZURNAI (AUTOINJECTOR)	nalmefene hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	218590-001	Aug 7, 2024		RX	Yes	Yes	11,865,112	⤷ Start Trial	Y			⤷ Start Trial
Purdue Pharma Lp	ZURNAI (AUTOINJECTOR)	nalmefene hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	218590-001	Aug 7, 2024		RX	Yes	Yes	11,857,547	⤷ Start Trial	Y			⤷ Start Trial
Purdue Pharma Lp	ZURNAI (AUTOINJECTOR)	nalmefene hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	218590-001	Aug 7, 2024		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for ZURNAI (AUTOINJECTOR)

See the table below for patents covering ZURNAI (AUTOINJECTOR) around the world.

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
China	101132820	Prefilled needle assisted jet injector	⤷ Start Trial
South Korea	20140050663	INJECTION DEVICE WITH CAMMED RAM ASSEMBLY	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2013152323		⤷ Start Trial
Japan	7549576		⤷ Start Trial
Brazil	PI0614025	injetores de jato	⤷ Start Trial
Australia	2019376633		⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.